Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 BNT162b2 mRNA vaccinees. We tested their total S-Ab...
Main Authors: | Chin Shern Lau, John Thundyil, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu, Tar Choon Aw |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4468/11/4/70 |
Similar Items
-
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
by: Samar Samoud, et al.
Published: (2023-08-01) -
Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01) -
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
by: Daniel Leung, et al.
Published: (2022-09-01) -
Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
by: Ruiqi Zhang, et al.
Published: (2022-04-01) -
Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)